Management of Uterine Leiomyomata and Adenomyosis : Role of Hysteroscopy in Diagnosis and Norethisterone in the Treatment

Ahmed Ali Mahmoud2 sites in 1 country100 target enrollmentApril 10, 2021

ConditionsAbnormal Uterine Bleeding

InterventionsNorethisterone acetate

DrugsNorethisterone acetate

Overview

Phase: Not Applicable
Intervention: Norethisterone acetate
Conditions: Abnormal Uterine Bleeding
Sponsor: Ahmed Ali Mahmoud
Enrollment: 100
Locations: 2
Primary Endpoint: is to evaluate sensitivity and specificity of hysteroscopy in differentiating between uterine adenomyosis and leiomyomatosis
Last Updated: 4 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

to determine the role of hysteroscopy and guided biopsy to differentiate between submucosal fibroids and adenomyosis confirmed by histopathological examination
to evaluate the efficacy of norethisterone in the treatment of symptomatic adenomyosis and leiomyoma

Detailed Description

The aim of the present study is: 1. to determine the role of hysteroscopy and guided biopsy to differentiate between submucosal fibroids and adenomyosis confirmed by histopathological examination 2. to evaluate the efficacy of norethisterone in the treatment of symptomatic adenomyosis and leiomyoma

Registry

clinicaltrials.gov

Start Date

April 10, 2021

End Date

December 25, 2021

Last Updated

4 years ago

Study Type

Observational

Sex

Female

Investigators

Sponsor

Ahmed Ali Mahmoud

Responsible Party

Sponsor Investigator

Principal Investigator

Ahmed Ali Mahmoud

Assiut University

Eligibility Criteria

Inclusion Criteria

•(1) age≥30 years; (4) dysmenorrhea, adenomyosis-associated chronic pain, and/or menorrhagia.
•(3) regular menstrual cycles before administration of norethisterone; (4) no other treatment for adenomyosis/leiomyomatosis at least for 3 months biopsies and histopathology for operated patients;

Exclusion Criteria

•(1) pregnant and/or breast-feeding women (2) patients with a ovarian neoplasm, benign ovarian cyst including endometrioma, pelvic inflammatory disease or other endocrine diseases.